Protox releases Q2 2007 financial results and company highlightsCNW Telbec (Communiqués de presse), Canada - Aug 30, 2007A Phase 2a clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track …
Read full story
TGF–induced EMT: mechanisms and implications for fibrotic lung …AJP-Lung Physiology (subscription) - Aug 29, 2007Cross talk has also been demonstrated between TGF- and Notch signaling, although the downstream mediators of EMT are unknown, and a role for this pathway in …
Read full story
Nexavar Significantly Improved Overall Survival in Phase 3 Asia …CNNMoney.com - Aug 26, 2007(5) This double-blind, randomized, placebo-controlled Phase 3 trial was designed to evaluate Nexavar in patients with advanced HCC, or primary liver cancer, …
Read full story
Nexavar Granted FDA Priority Review for Treatment of Liver CancerCNNMoney.com - Aug 20, 2007HCC, the most common form of liver cancer, is responsible for about 90 percent of the primary malignant liver tumors in adults.(1,2) Liver cancer is the …
Read full story
Protox acquires research program from MedicennaCanada NewsWire (press release), Canada - Aug 21, 2007In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. …
Read full story
Protox acquires research program from MedicennaCNW Telbec (Communiqués de presse), Canada - 3 hours agoIn addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. …
Read full story
Nexavar Granted FDA Priority Review for Treatment of Liver CancerPR Newswire (press release), NY - Aug 20, 2007HCC, the most common form of liver cancer, is responsible for about 90 percent of the primary malignant liver tumors in adults.(1,2) Liver cancer is the …
Read full story
Rosetta sees first product launches in 2008Globes, Israel - Aug 6, 2007… Henry Ford Hospital in Detroit, Michigan, which will provide samples for the clinical validation of its Cancer of Unknown Primary (CUP) diagnostic test. …
Read full story
Protox Announces Manufacturing Agreement with Dompé for PRX321PharmaLive.com (press release), PA - Jul 18, 2007In addition, a Phase 1 clinical trial evaluating PRX321 for the treatment of patients with renal cell carcinoma and non-small cell lung cancer has been …
Read full story
Rosetta Genomics Reports Second Quarter 2007 Financial ResultsCNNMoney.com - 4 hours agoRosetta Genomics continues to advance its lead diagnostic program for Cancer of Unknown Primary (CUP). The Company believes that by using a panel of only 28 …
Read full story
ImClone Systems Reports Second Quarter 2007 Financial ResultsGenetic Engineering News (press release), NY - 1 hour agoERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the …
Read full story
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment …New England Journal of Medicine (subscription), MA - 3 hours agoInclusion criteria were as follows: histologically proven colorectal carcinoma of stage III (any tumor stage, N1 or 2, and M0) or stage II (T3 or 4, N0, …
Read full story
Pokey’s Hope joins 4800 riders for Pan-Massachusetts ChallengeNashua Telegraph (subscription), NH - 9 hours agoThe cancer that took Grindle from his family, adenoma carcinoma of unknown primary, had no identifiable source. He was diagnosed in October 2004 and …
Read full story